We are live on ! Find out more
KERX

Keryx Biopharmaceuticals Inc
KERX

Delisted

KERX was delisted on the 12th of December, 2018.

150 hedge funds and large institutions have $1.14B invested in Keryx Biopharmaceuticals Inc in 2014 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 52 increasing their positions, 44 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

173% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 15

73% more capital invested

Capital invested by funds: $660M → $1.14B (+$484M)

21% more funds holding

Funds holding: 124150 (+26)

18% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 44

17% more funds holding in top 10

Funds holding in top 10: 67 (+1)

12% more call options, than puts

Call options by funds: $32.6M | Put options by funds: $29.1M

Holders
150
Holders Change
+26
Holders Change %
+20.97%
% of All Funds
4.33%
Holding in Top 10
7
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+16.67%
% of All Funds
0.2%
New
41
Increased
52
Reduced
44
Closed
15
Calls
$32.6M
Puts
$29.1M
Net Calls
+$3.44M
Net Calls Change
-$4.51M
Name Holding Trade Value Shares
Change
Change in
Stake
New York State Common Retirement Fund
101
New York State Common Retirement Fund
New York
$522K
1CM
102
1492 Capital Management
Wisconsin
$520K +$460K +30,501 New
Susquehanna International Group
103
Susquehanna International Group
Pennsylvania
$493K -$13.1M -868,170 -97%
T. Rowe Price Associates
104
T. Rowe Price Associates
Maryland
$484K
Citigroup
105
Citigroup
New York
$477K -$126K -8,349 -23%
PAM
106
Paradigm Asset Management
New York
$435K -$30.2K -2,000 -7%
LPL Financial
107
LPL Financial
California
$424K +$113K +7,518 +43%
Two Sigma Investments
108
Two Sigma Investments
New York
$397K -$141K -9,347 -29%
TRCT
109
Tower Research Capital (TRC)
New York
$341K +$302K +19,984 New
MCM
110
Munder Capital Management
Michigan
$327K -$12.4K -825 -4%
Millennium Management
111
Millennium Management
New York
$325K -$3.15M -208,614 -92%
GCP
112
GSA Capital Partners
United Kingdom
$325K +$288K +19,062 New
Renaissance Technologies
113
Renaissance Technologies
New York
$319K +$282K +18,700 New
GGHC
114
Gilder Gagnon Howe & Co
New York
$317K -$1.84K -122 -0.7%
BWP
115
Baldwin Wealth Partners
Massachusetts
$224K -$153K -10,149 -44%
ST
116
Spot Trading
Illinois
$188K -$3.55M -235,548 -96%
Barclays
117
Barclays
United Kingdom
$187K -$560K -37,128 -77%
KB
118
Kimelman & Baird
New York
$170K
Creative Planning
119
Creative Planning
Kansas
$164K -$45.3K -3,000 -24%
FMT
120
First Mercantile Trust
Tennessee
$164K +$146K +9,645 New
MCM
121
Manchester Capital Management
Vermont
$146K +$129K +8,580 New
Group One Trading
122
Group One Trading
Illinois
$136K -$4.95M -328,193 -98%
LTFS
123
Ladenburg Thalmann Financial Services
Florida
$133K -$7.83K -519 -6%
WAM
124
Wolverine Asset Management
Illinois
$119K -$9.05K -600 -8%
Royal Bank of Canada
125
Royal Bank of Canada
Ontario, Canada
$112K -$272K -18,050 -73%

KERX Hedge Fund Activity: Q1 2014 in Review

150 of the 3,464 institutional investors tracked by Wall St. Rank reported a position in Keryx Biopharmaceuticals Inc (KERX) for Q1 2014, worth a combined $1.14B — up 73% from $660M a quarter earlier.

Buyers outnumbered sellers: 41 funds opened new KERX positions and 15 closed out — a net gain of 26 holders — while 52 added to existing stakes and 44 trimmed.

The largest buyer was Baupost Group, opening a new position worth an estimated $95.2M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $22M sold.

  • 150 institutional investors held Keryx Biopharmaceuticals Inc (KERX) as of Q1 2014, up from 124 in Q4 2013.
  • Funds reported $1.14B of Keryx Biopharmaceuticals Inc stock for Q1 2014, up 73% quarter-over-quarter.
  • 41 funds opened new Keryx Biopharmaceuticals Inc positions in Q1 2014 and 15 closed out, a net change of +26 holders.
  • The largest Keryx Biopharmaceuticals Inc buyer in Q1 2014 was Baupost Group, an estimated $95.2M added.
  • The largest Keryx Biopharmaceuticals Inc seller in Q1 2014 was Cormorant Asset Management, an estimated $22M sold.

Based on aggregated 13F filings for Q1 2014.